Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis

British Journal of Cancer

Volumn 87, Issue 11, 2002, Pages 1287-1293

  Yousef, G M ^a,b   Borgono C A ^a,b   Scorilas, A ^c   Ponzone, R ^d   Biglia, N ^d   Iskander, L ^b   Polymeris, M E ^b   Roagna, R ^d   Sismondi, P ^d   Diamandis, E P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; Cancer genes; Kallikreins; KLK14; Predictive factors; Prognostic; Serine proteases; Tumour markers

Indexed keywords

ANDROGEN; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; KALLIKREIN; KALLIKREIN 14; PROGESTERONE; PROGESTERONE RECEPTOR; STEROID HORMONE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER STAGING; CANCER SURVIVAL; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; OVARY CELL CULTURE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STATISTICAL ANALYSIS; TESTIS TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL;

EID: 0037132384     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600623     Document Type: Article

References (56)

1. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R (1996) A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2: 624-636
2. Barry MJ (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344: 1373-1377
3. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD (1995) Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochera Mol Biol 52: 459-467
4. Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377
5. Brys M (2000) Androgens and androgen receptor: Do they play a role in breast cancer? Med Sci Monit 6: 433-438
6. Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27: 137-142
7. Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK (1994) Prognostic factors: Rationale and methods of analysis and integration. Breast Cancer Res Treat 32: 105-112
8. Cox DR (1972) Regression models and life tables. R Stat Soc B 34: 187-202
9. Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO (2001) Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 54: 20-24
10. Diamandis EP (1998) Prostate-specific antigen - Its usefulness in clinical medicine. Trends Endocrinol Metab 9: 310-316
11. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N (2002) Human kallikrein 11: A new biomarker of prostate and ovarian carcinoma. Cancer Res 62: 295-300
12. Diamandis EP, Yousef GM (2001) Human tissue kallikrein gene family: A rich source of novel disease biomarkers. Expert Rev Mol Diagn 1: 182-190
13. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H (2000a) New nomenclature for the human tissue kallikrein gene family. Clin Chem 46: 1855-1858
14. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV (2000b) The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab 11: 54-60
15. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P (2000c) Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 33: 579-583
16. Duffy MJ (1991) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metast 10: 145-155
17. Duffy MJ (2001) Biochemical markers in breast cancer: Which ones are clinically useful? Clin Biochem 34: 347-352
18. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N (1999) Urokinase plasminogen activator: A prognostic marker in multiple types of cancer. J Surg Oncol 71: 130-135
19. EORTC (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 16: 1513-1515
20. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978
21. Gottesman M (1990) The role of proteases in cancer. Semin Cancer Biol 1: 97-160
22. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Holzel F, Schulz KD (1991) Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res 51: 5722-5727
23. Hamilton A, Piccart M (2000) The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11: 647-663
24. Herszenyi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F (1999) The role of cysteine and serine proteases in colorectal carcinoma. Cancer 86: 1135-1142
25. Hooper JD, Bui LT, Rae FK, Harvey TJ, Myers SA, Ashworth LK, Clements JA (2001) Identification and characterization of klk14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genoraics 73: 117-122
26. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52: 23-47
27. Kim H, Scorilas A, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, Piccinno R, Gordini G, Diamandis EP (2001) Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84: 643-650
28. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Janicke F, Schmitt M, Graeff H (1999) Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79: 1746-1751
29. Lea OA, Kvinnsland S, Thorsen T (1989) Improved measurement of androgen receptors in human breast cancer. Cancer Res 49: 7162-7167
30. Liao DZ, Pantazis CG, Hou X, Li SA (1998) Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: Probable mediation by steroid receptors. Carcinogenesis 19: 2173-2180
31. Luo LY, Bunting P, Scorilas A, Diamandis EP (2001a) Human kallikrein 10: A novel tumor marker for ovarian carcinoma? Clin Chim Acta 306: 111-118
32. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP (2001b) Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 7: 2372-2379
33. Luo LY, Rajpert-De Meyts ER, Jung K, Diamandis EP (2001c) Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 85: 220-224
34. Magklara A, Scorilas A, Catalona WJ, Diamandis EP (1999) The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45: 1960-1966
35. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP (2001) The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 7: 806-811
36. Maguire TM, Shering SG, Duggan CM, McDermott EW, O'Higgins NJ, Duffy MJ (1998) High levels of cathepsin B predict poor outcome in patients with breast cancer, Int J Biol Markers 13: 139-144
37. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
38. Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP (2001) Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 7: 2380-2386
39. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841
40. Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822
41. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW (1998) Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35: 275-368
42. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive Factor, and target for therapy. Oncologist 3: 237-252
43. Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49-61
44. Scorilas A, Yotis J, Pateras C, Trangas T, Talieri M (1999) Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 5: 815-821
45. Smith RA, Von Eschenbach AC, Wender A, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V, Eyre H (2001) American Cancer Society guidelines for early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers, and update 2001. Testing for early lung cancer detection. CA Cancer J Clin 51: 7-38
46. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S (1992) Androgen receptors in operable breast cancer: Relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18: 112-118
47. Xie B, Tsao SW, Wong YC (1999) Sex hormone-induced mammary carcinogenesis in female noble rats: The role of androgens. Carcinogenesis 20: 1597-1606
48. Yousef GM, Chang A, Diamandis EP (2000a) Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 275: 11891-11898
49. Yousef GM, Chang A, Scorilas A, Diamandis EP (2000b) Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 276: 125-133
50. Yousef GM, Magklara A, Diamandis EP (2000c) KLK12 is a novel serine protease and a new member of the human kallikrein gene family - Differential expression in breast cancer. Genomics 69: 331-341
51. Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 22: 184-204
52. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D (2001a) Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: A new independent and favorable prognostic marker. Cancer Res 61: 7811-7818
53. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP (2001b) Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 61: 3425-3431
54. Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP (2001c) Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 276: 53-61
55. Yousef GM, Diamandis EP (2002) Human kallikreins: Common structural features, sequence analysis and evolution. Curr Genom In Press
56. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P (1995) Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104-2110